GlassScriptPhysician profile
Van Bich Barros
NPI 1932628104
$1,017.28
in general payments reported to CMS, 2019-2025
17 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $185 · 2023: $396 · 2024: $194 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.97 |
| Education | $214.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $276.01 | 2021-2024 | Erleada, Akeega |
| Astellas Pharma US INC | $159.87 | 2023 | Veozah |
| Abbvie INC. | $100.27 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.16 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $55.49 | 2022-2025 | Keytruda |
| Boston Scientific Corporation | $54.40 | 2022-2024 | Ams 700 |
| Sumitomo Pharma America, INC. | $51.21 | 2023-2024 | Gemtesa |
| Progenics Pharmaceuticals, INC. | $49.48 | 2025 | |
| 180 Medical, INC. | $44.89 | 2022-2023 | |
| Urogen Pharma, INC. | $31.75 | 2024 | |
| Clarus Therapeutics INC. | $28.72 | 2021 | |
| Tolmar, INC. | $19.02 | 2025 | Jatenzo, Eligard |
| Dendreon Pharmaceuticals LLC | $16.73 | 2025 | Provenge |
| Immunitybio, INC. | $16.71 | 2025 | |
| Endo Pharmaceuticals INC. | $14.58 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.96 | 2025 | |
| Sun Pharmaceutical Industries INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Barros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.